Dosage Forms

Articles

Dyadic International has announced its collaboration agreement with Serum Institute of India for the development and manufacture of up to 12 antibodies and vaccines using Dyadic’s C1 gene expression system.


Dyadic, Serum Institute of India Collaborate on Affordable and Accessible Antibodies

AbCellera, Niaid Vaccine Research Center, and Ichor Medical Systems have formed a partnership to develop an end-to-end platform capable of developing field-ready, nucleic acid-based countermeasures against a pandemic strain of influenza.

Partnership to Address Pandemic Viral Outbreaks

The Vaccine Development and Bioprocess Cell Culture Technology Day will take place on May 16, 2019 in Baltimore, MD.

Eppendorf Hosts Vaccine Development and Bioprocess Cell Culture Technology Day

Dengvaxia is the first FDA-approved vaccine for dengue disease caused by all dengue virus serotypes for individuals ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.

FDA Approves First Vaccine for Dengue Disease

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Pharma delivers a positive message with renewed efforts to eradicate malaria.

Working for the Greater Good

The World Health Organization (WHO) has welcomed the launch of a malaria vaccine in a pilot program taking place in Malawi, Africa.

World’s First Malaria Vaccine Launched in Malawi

Seqirus has taken the decision to make its cell-based flu vaccine, FLUCELVAX TETRA, using a completely cell-based production process.


Seqirus to Manufacture Flu Vaccine Using Cell-Based Production Processes

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Patient-centric drug development is becoming more important in the bio/pharma industry.

Designed with the Patient in Mind

The company received $4.8 million from the Bill & Melinda Gates Foundation to accelerate global health research in the development of vaccines and antibody-based treatments for infectious diseases.

AbCellera is Funded $4.8 Million for Vaccine and Antibody Research

Procarta Biosystems has received investment from Novo Holdings REPAIR Impact Fund to the tune of €1.5 million, which will be used to develop a new class of antibiotics to tackle AMR.

Vaccines